Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company, is making strides in the treatment of cutaneous T-cell lymphoma (CTCL) with its lead candidate, PTX-100. The company is focused on developing novel therapies to improve outcomes for cancer patients. Prescient’s technologies include targeted and cell therapies, aiming to provide more effective and safer treatments.
Phase 2a trial data has revealed a 64% tumour halt or shrinkage rate in patients with CTCL, a rare and aggressive cancer. This is a notable improvement compared to existing therapies, which offer only a 36% chance of relief and are associated with significant adverse effects in 98% of patients. In contrast, PTX-100 demonstrated a more favourable safety profile, with only 4% of patients reporting serious adverse effects.
Chief executive officer James McDonnell believes these trial results position Prescient to become a prominent Australian biotech success story. The company has received orphan drug and fast track designations from the US Food and Drug Administration (FDA), potentially accelerating the drug’s path to commercialisation. These designations offer market exclusivity and the opportunity to expedite clinical trials, underscoring the potential of PTX-100 to address a significant unmet need in CTCL treatment.
Prescient is also advancing its OmniCAR and CellPryme platforms for CAR-T therapies, representing the next generation of cancer care. These platforms aim to enhance the targeting, safety, and cost-effectiveness of cell therapies, further solidifying Prescient’s commitment to transforming cancer treatment.
